Opening Ceremony Performance
Prof. Dr. Mehmet Cahit Güran (Rector of Hacettepe University)
Prof. Dr. Ümit Kervan (TÜSEB President, in case of participation)
Prof. Dr. Kemal Memişoğlu (Minister of Health, in case of participation)
Türkiye’de Farmasötik Etkin Madde (API) ve Aşı Üretiminin Güncel Durumu ve Gelecek Stratejileri
Prof. Dr. Mutlu Aytemir, Hacettepe Üniversitesi Eczacılık Fakültesi Dekanı
Uzm. Ecz. Taner Ercanlı - Türk Eczacılar Birliği (TEB) Genel Sekreteri
Guilhem Granier, Head of EURASIA MCO & General Manager Turkey - VACCINES, SANOFI TÜRKİYE
Turgay Kaçar Atabay Biyoteknoloji - ATABAY İLAÇ
Dr. Kimyager A. Neşe Kayran (Stratejik Portföy ve Projeler Müdürü) - NOBEL İLAÇ
Dr. Ecz. Abdullah Uslu (Gebze ArGe ve Biyoteknoloji Müdürü) - NOBEL İLAÇ
Small Molecule Inhibition And Protein-Targeted Degradation Of Class I HDACs As Effective Therapeutic Strategies
Prof. Dr. Giuseppe Campiani
From Molecular Design to Biological Activity: New Directions in Anticancer and Alzheimer’s Therapeutics
Prof. Dr. Reem K. Arafa
Synthetic products referencing biologically produced peptides
Moderator & Speaker: Işıl Canset Cantürk Üçtuğ & Speaker: Morten Hach & Panelist: Jens Heisterberg
TACC3 Inhibition as a Precision Oncology Approach for Aggressive Solid Cancers
Prof. Dr. Erden Banoğlu
Exploring the Modulation of Bacterial Carbonic Anhydrases for the Prevention and Treatment of Infectious Diseases
Assoc. Prof. Dr. Simone Carradori
timsOmni – a Revolutionary Tool for Top-Down Protein Characterization and beyond
Speaker: Daniel Vláčil
Chiral Drugs: Current Trends and Analytical Challenges
Prof. Dr. Bezhan Chankvetadze
Structure- and Data-Driven Kinase Inhibitor Discovery: Integrating Pharmacophore Modeling, Docking, and Machine Learning for Lead Identification and Optimization
Prof. Dr. Mutasem O. Taha
to be announced
Prof. Dr. Burak Civelek
ORGANOID TECHNOLOGIES: New Perspectives in Drug Development and Personalized Medicine
Prof. Dr. Fatma Duygu Özel Demiralp
OP01 - OP03
Darizmetinib: A Promising 1st-in-Class Liver Regenerating Drug in Phase 1b/2a Clinical Development, Targeting the Stress Signaling Protein Kinase MKK4
Prof. Dr. Stefan Laufer
From Selective to Multitarget-Directed Ligands: Endocannabinoid Catabolism as a Therapeutic Strategy in Epilepsy and Neuroinflammatory conditions
Prof. Dr. Stefania Butini
The Living Scaffold: Designing Anti-cancer T Cell Therapies for the Modern Pharmacopeia
Prof. Dr. Güneş Esendağlı
Integrative Computational, Molecular, and Systems-Level Approaches to Target Matrix Metalloproteinases: From Inhibitor Design to Precision Modulation in Disease.
Prof. Dr. Sanaa K. Bardaweel
Integrated R&D Strategies for Nitrosamine/GTI Control: From Root Causes to Sustainable Solutions
Dr. Manik Reddy Pullagurla
Reinventing azoles: New Tricks From Old Drugs Via Metal Complexation
Prof. Dr. Sandra Vojnović
Green Technologies in Pharmaceutical Chemistry: Berberine-Rich Extract for Sustainable Therapeutic Applications
Assist. Prof. Dr. Muhammad Ajmal Shah